"The Ministry of Agriculture informed that in India, if no further import of raw material is allowed, the existing stock should be depleted within a period of two years after its manufacture.
"Taking into consideration all these facts, the Committee felt that that to exhaust the available stocks of the raw material, manufacture and use of Endosulfan may be permitted for a total period of two years," the report, filed before a bench of justices Swatanter Kumar and Madan B Lokur, said.
The recommendations of the expert committee, headed by Indian Council of Medical Research scientist R S Dhaliwal, would now be considered by the court on November 29.
The panel, in its report, said, "The manufacturing and marketing companies should be asked to ensure to completely exhaust the available raw material during this period and ensure that that this pesticide is fully utilised in accordance with label claim and good agricultural practices for pest control."
The court-appointed committee observed that Endosulfan has "important health hazards/biological effects related to endocrine disruption, carcinogenicity, congenital anomalies and reproductive and neurological abnormalities."
The report also said that other pesticides "by nature, are toxic compound" having certain "unwanted effects".
The court is hearing a petition filed by Democratic Youth Federation of India that sought a ban on Endosulfan on the ground that it was causing health hazards including genetic disorders. (More)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
